Christoph Lawrence Bausch - 26 Aug 2025 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: CHIEF OPERATING OFFICER
Signature: /s/ Christoph Bausch
Issuer symbol: SABS
Transactions as of: 26 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Aug 2025, 17:00:09 UTC
Previous filing: 23 Feb 2024
Next filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bausch Christoph Lawrence	CHIEF OPERATING OFFICER	2100 E 54TH STREET NORTH, SIOUX FALLS	/s/ Christoph Bausch	28 Aug 2025	0001889981

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SABS	Stock Option (right to buy)	Award	$0	+600,000		$0.000000	600,000	26 Aug 2025	Common Stock	600,000	$2.17	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").
F2	The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.
F3	The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.